Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2051250120) titled 'A Phase 3 Study of JNT-517 in Participants with Phenylketonuria' on Sept. 29.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Leslyn Hermonstine
Condition:
Phenylketonuria
Intervention:
Period 1: Administer JNT-517 at 75 mg tablets or 150 mg tablets or Placebo orally twice daily for 6 weeks. Period 2: Administer JNT-517 at 75 mg tablets or 150 mg tablets orally twice daily for 46 weeks.
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 25/11/2025
Target Sample Size: 6 ...